| Not Yet Recruiting | Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukem NCT07437950 | National Cancer Institute (NCI) | Phase 2 |
| Not Yet Recruiting | A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell NCT07498465 | Children's Oncology Group | Phase 1 |
| Not Yet Recruiting | Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patien NCT07463768 | French Innovative Leukemia Organisation | Phase 2 |
| Not Yet Recruiting | Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia NCT07411586 | M.D. Anderson Cancer Center | Phase 1 |
| Not Yet Recruiting | my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults NCT07516353 | Dana-Farber Cancer Institute | N/A |
| Not Yet Recruiting | Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia NCT07022678 | Children's Oncology Group | Phase 3 |
| Not Yet Recruiting | Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML NCT07511062 | Northside Hospital, Inc. | Phase 1 |
| Not Yet Recruiting | Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood NCT06954987 | National Cancer Institute (NCI) | Phase 2 |
| Not Yet Recruiting | Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following NCT05554419 | National Cancer Institute (NCI) | Phase 2 |
| Not Yet Recruiting | Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leu NCT07439211 | Jacqueline Garcia, MD | Phase 1 |
| Not Yet Recruiting | Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML NCT07374029 | David Avigan | Phase 1 |
| Not Yet Recruiting | Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX) NCT07528417 | University of Manitoba | Phase 2 |
| Not Yet Recruiting | Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukem NCT07094750 | Fred Hutchinson Cancer Center | N/A |
| Not Yet Recruiting | Motixafortide for MRD Sensitization in AML NCT07392970 | Washington University School of Medicine | Phase 2 |
| Not Yet Recruiting | Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT NCT07254793 | University of Arizona | Phase 1 |
| Not Yet Recruiting | Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; NCT07153497 | National Cancer Institute (NCI) | Phase 2 |
| Not Yet Recruiting | Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of G NCT06996119 | City of Hope Medical Center | Phase 1 |
| Recruiting | A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Vir NCT07020533 | City of Hope Medical Center | Phase 1 |
| Suspended | Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve O NCT06802523 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan a NCT07493538 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Not Yet Recruiting | Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Elig NCT06930352 | Uma Borate | Phase 2 |
| Recruiting | Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Elig NCT06782542 | Justin Watts, MD | Phase 2 |
| Not Yet Recruiting | HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors NCT07483749 | The Children's Hospital of Zhejiang University School of Medicine | — |
| Recruiting | High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leu NCT07177079 | Kittika Poonsombudlert | Phase 1 |
| Not Yet Recruiting | IFN-α in Relapse Prevention. NCT07449286 | Peking University People's Hospital | Phase 2 |
| Not Yet Recruiting | A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With NCT07255872 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 / Phase 3 |
| Recruiting | Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatm NCT07223814 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 3 |
| Recruiting | Evaluation of Chemotherapy-induced Cognitive Disorders During the Treatment of Hematological Malignancies NCT07147621 | University Hospital, Angers | — |
| Recruiting | First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-r NCT07384715 | Genmab | Phase 1 |
| Recruiting | Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic NCT07107126 | Remedy Plan, Inc. | Phase 1 |
| Not Yet Recruiting | GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia NCT07372885 | University of Manchester | Phase 1 / Phase 2 |
| Recruiting | De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients NCT06557421 | Institut Paoli-Calmettes | Phase 2 |
| Recruiting | FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia NCT07283094 | Montefiore Medical Center | Phase 1 |
| Recruiting | Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation NCT07130695 | Virginia Commonwealth University | Phase 1 |
| Not Yet Recruiting | Effect of Hypnosis and Virtual Reality on Anxiety During Treatment for Acute Myeloid Leukemia NCT07386392 | University Hospital, Toulouse | N/A |
| Not Yet Recruiting | Clinico-hematological and Coagulation Profiles in Newly Diagnosed Acute Myeloid Leukemia Patients Treated With NCT07343687 | Assiut University | — |
| Not Yet Recruiting | Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell NCT07432100 | Mingfeng Zhao | Phase 1 |
| Recruiting | Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS NCT07270978 | University of Virginia | Phase 1 |
| Not Yet Recruiting | Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients W NCT07407660 | Peking University People's Hospital | Phase 3 |
| Not Yet Recruiting | Design and Validation of a Generative AI and Propensity Score Matching Model for the VEN-DEC Phase II Study in NCT07420790 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | — |
| Not Yet Recruiting | Venetoclax Combined With Azacitidine for Consolidation Therapy in AML NCT07425782 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Recruiting | A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People W NCT07392242 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML NCT07259707 | First Affiliated Hospital of Zhejiang University | Phase 2 |
| Recruiting | Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients Wit NCT07243483 | Centre Leon Berard | N/A |
| Recruiting | A Study of Revumenib and Mezigdomide in People With Leukemia NCT07356154 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatr NCT07306832 | AbbVie | Phase 1 |
| Not Yet Recruiting | A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients NCT07303660 | Lomond Therapeutics Holdings, Inc. | Phase 1 |
| Not Yet Recruiting | Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML NCT07157514 | Actinium Pharmaceuticals | Phase 2 / Phase 3 |
| Not Yet Recruiting | Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT NCT07319793 | Peking University People's Hospital | N/A |
| Withdrawn | A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participan NCT05521087 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Mye NCT07304011 | University of California, Davis | Phase 2 |
| Recruiting | Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acut NCT07228273 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT NCT06551584 | Stanford University | Phase 1 |
| Recruiting | A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia NCT07295951 | Janssen Research & Development, LLC | Phase 1 |
| Not Yet Recruiting | Observational Study on APL-like aCute Myeloid Leukemia: disTInct Phenotype and Early VAscular complicaTions NCT07080970 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Recruiting | UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML NCT07059975 | Joanna Yi | EARLY_Phase 1 |
| Recruiting | Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life NCT06710418 | University of Washington | N/A |
| Not Yet Recruiting | Study of Management and Prognosis of Patients With Acute Myeloblastic Leukemia in Saint-Antoine Hospital NCT05558943 | Assistance Publique - Hôpitaux de Paris | — |
| Not Yet Recruiting | Expression Pattern and Possible Clinical Significance of CD81 In Myeloid Leukemia NCT07146542 | Assiut University | — |
| Recruiting | Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and NCT07046078 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell NCT06928662 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | Molecular Characterization of Carbapenemase-Producing Enterobacterales NCT07116356 | Sohag University | N/A |
| Recruiting | Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia NCT06599762 | University of Manitoba | Phase 2 |
| Recruiting | Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia NCT07144020 | Zhejiang University | EARLY_Phase 1 |
| Not Yet Recruiting | The Prognostic Significance of Platelet to White Blood Cell Ratio (PWR) in Patients With Acute Myeloid Leukemi NCT07115537 | Assiut University | — |
| Recruiting | Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT NCT07183878 | First Affiliated Hospital of Zhejiang University | N/A |
| Recruiting | Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients Wi NCT06484062 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukem NCT07108530 | Shanxi Bethune Hospital | Phase 2 |
| Recruiting | Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML NCT07075016 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 3 |
| Recruiting | Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant NCT06129734 | Benjamin Tomlinson | Phase 1 / Phase 2 |
| Recruiting | Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants NCT07019155 | National Cancer Institute (NCI) | — |
| Recruiting | Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutane NCT07044687 | AbbVie | Phase 4 |
| Recruiting | Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in NCT06824168 | Daiichi Sankyo | Phase 2 |
| Recruiting | Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies NCT07044544 | University of Alabama at Birmingham | Phase 1 |
| Recruiting | Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial) NCT06513273 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Recruiting | Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia NCT06769490 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagn NCT07008638 | Masonic Cancer Center, University of Minnesota | Phase 1 / Phase 2 |
| Recruiting | 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid NCT06287944 | City of Hope Medical Center | Phase 1 |
| Not Yet Recruiting | Repurposing Itraconazole as an Adjuvant Therapy in Treatment of Patients With Acute Myeloid Leukemia: Is it a NCT07069933 | Mansoura University | Phase 2 |
| Recruiting | CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies NCT07106749 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Recruiting | ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia NCT06945042 | Wake Forest University Health Sciences | N/A |
| Recruiting | Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML NCT07078591 | Beijing 302 Hospital | Phase 2 |
| Recruiting | VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma NCT07028086 | Ruijin Hospital | Phase 2 |
| Recruiting | A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute My NCT06903702 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Home Blood Transfusions NCT07121140 | Thomas Jefferson University | N/A |
| Not Yet Recruiting | Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia NCT06667973 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Phase 2 |
| Recruiting | Romiplostim N01 for Platelet Recovery After Haploidentical HSCT NCT07321626 | First Affiliated Hospital of Zhejiang University | Phase 1 |
| Recruiting | a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia NCT07007949 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Recruiting | A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acut NCT06969430 | Debiopharm International SA | Phase 1 / Phase 2 |
| Recruiting | XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remis NCT06980155 | Shanghai Jiao Tong University School of Medicine | EARLY_Phase 1 |
| Withdrawn | TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant NCT05968170 | Neena Kapoor, M.D. | N/A |
| Recruiting | A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia NCT06810583 | St. Jude Children's Research Hospital | Phase 1 |
| Recruiting | A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the NCT06880354 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Recruiting | Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change ( NCT06672146 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic NCT07256210 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 2 |
| Active Not Recruiting | Extension Study, Pilot, Compassionate Use of Azacitidine 300 mg Film Coated Tablets for Acute Myeloid Leukaemi NCT06572982 | Hikma Pharmaceuticals LLC | N/A |
| Not Yet Recruiting | Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients NCT06900088 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Vers NCT06815003 | City of Hope Medical Center | Phase 2 |
| Recruiting | CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF) NCT06834282 | CERo Therapeutics Holdings, Inc. | Phase 1 |
| Withdrawn | Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HM NCT05766514 | University of Florida | Phase 2 |
| Recruiting | Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML NCT06737523 | The First Affiliated Hospital of Xiamen University | Phase 1 |
| Recruiting | A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) NCT06950034 | Solu Therapeutics, Inc | Phase 1 |
| Recruiting | A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab NCT06448013 | M.D. Anderson Cancer Center | Phase 1 |
| Not Yet Recruiting | Epidemiology of Infection in Acute Myeloid Leukemia (AML) NCT06797648 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. NCT06713837 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 3 |
| Recruiting | UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia NCT06245746 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 |
| Recruiting | Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid Leukemia NCT06535113 | Ciceri Fabio | — |
| Recruiting | Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia NCT06445907 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Oral-ATO for TP53-mutated Myeloid Malignancies NCT06778187 | The University of Hong Kong | Phase 2 |
| Not Yet Recruiting | Expectations of Patients in Palliative Situation NCT06786897 | University Hospital, Montpellier | — |
| Enrolling By Invitation | Daunorubicin + Cytarabine + Venetoclax in de Novo AML NCT06697327 | Anhui Medical University | N/A |
| Recruiting | Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Le NCT06816134 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Recruiting | A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malig NCT06616636 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Do NCT06498973 | City of Hope Medical Center | Phase 1 |
| Recruiting | Massage Impact on Sleep in Pediatric Oncology NCT06892158 | Children's Hospital of Philadelphia | N/A |
| Recruiting | Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell T NCT06543381 | City of Hope Medical Center | Phase 1 |
| Recruiting | A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute My NCT06456463 | Stemline Therapeutics, Inc. | Phase 2 |
| Recruiting | A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies NCT06820268 | NovaOnco Therapeutics Co., Ltd. | Phase 1 |
| Recruiting | A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Le NCT06762132 | Zhejiang University | EARLY_Phase 1 |
| Completed | Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant NCT06734585 | Astellas Pharma Singapore Pte. Ltd. | — |
| Recruiting | Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the NCT06504459 | OHSU Knight Cancer Institute | Phase 2 |
| Not Yet Recruiting | ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute NCT06463327 | TC Biopharm | Phase 1 |
| Recruiting | BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia NCT06746519 | Chen Suning | Phase 1 / Phase 2 |
| Withdrawn | A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants NCT05367401 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Recruiting | Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azac NCT06514261 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia NCT06668558 | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias | Phase 2 |
| Recruiting | Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients NCT06651866 | The First Affiliated Hospital of Xiamen University | Phase 1 |
| Recruiting | Revumenib in Combination With 7+3 + Midostaurin in AML NCT06313437 | Richard Stone, MD | Phase 1 |
| Recruiting | Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant NCT06575296 | City of Hope Medical Center | Phase 1 |
| Suspended | Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients NCT06158100 | Antonio M Jimenez Jimenez | Phase 1 |
| Recruiting | HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML NCT06594445 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Recruiting | Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequ NCT06370000 | Virginia Commonwealth University | Phase 4 |
| Recruiting | Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD NCT06511882 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Recruiting | Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relap NCT06452732 | Peking University People's Hospital | — |
| Recruiting | The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA NCT06458257 | Ruijin Hospital | — |
| Withdrawn | Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS NCT05823480 | City of Hope Medical Center | Phase 1 |
| Not Yet Recruiting | TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome o NCT06602323 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Phase 2 |
| Not Yet Recruiting | Twice-per-weekSelinexor, 2 Days Melphalan NCT06613035 | Institute of Hematology & Blood Diseases Hospital, China | Phase 3 |
| Recruiting | Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A Myelo NCT06317649 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid NCT05554406 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplasti NCT06529731 | Sawa Ito, MD | Phase 2 |
| Recruiting | A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML NCT06284486 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of P NCT06439199 | Nantes University Hospital | — |
| Suspended | DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hem NCT06492707 | Fred Hutchinson Cancer Center | Phase 1 |
| Recruiting | The Efficacy of Allo-HSCT in ND HR-CBF-AML NCT06458244 | Ruijin Hospital | — |
| Not Yet Recruiting | CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML NCT06470841 | Navy General Hospital, Beijing | Phase 2 |
| Recruiting | Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + NCT05554393 | National Cancer Institute (NCI) | Phase 2 |
| Not Yet Recruiting | Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leu NCT06497062 | Shanghai Jiao Tong University School of Medicine | Phase 2 |
| Not Yet Recruiting | VA as Maintenance Therapy Post Allo-HSCT in MDS and AML NCT06598384 | Navy General Hospital, Beijing | Phase 2 |
| Withdrawn | Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant NCT06337331 | Northside Hospital, Inc. | Phase 2 |
| Suspended | 2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML NCT06626633 | University of Maryland, Baltimore | Phase 1 |
| Recruiting | Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia NCT06357182 | OHSU Knight Cancer Institute | Phase 1 |
| Recruiting | Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML NCT06451861 | Guangdong Provincial People's Hospital | Phase 2 |
| Recruiting | A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Tr NCT05589896 | Ossium Health, Inc. | Phase 1 / Phase 2 |
| Recruiting | Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia NCT06399640 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Terminated | A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hema NCT06508489 | Sanofi | Phase 1 / Phase 2 |
| Completed | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignanc NCT06492304 | CRISPR Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia NCT06386302 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Withdrawn | Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia NCT05720988 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Recruiting | Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy NCT06510868 | University Health Network, Toronto | — |
| Recruiting | Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hig NCT06013423 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR NCT06571825 | He Huang | Phase 4 |
| Recruiting | Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and NCT06128070 | City of Hope Medical Center | Phase 2 |
| Recruiting | CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Pat NCT06059391 | City of Hope Medical Center | Phase 2 |
| Recruiting | Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML NCT06420063 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed E NCT06621199 | First Affiliated Hospital of Zhejiang University | Phase 2 |
| Recruiting | Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-ri NCT06483906 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 2 |
| Not Yet Recruiting | A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) NCT06441084 | Nuwacell Biotechnologies Co., Ltd. | Phase 1 |
| Recruiting | BeFluBu vs FluBuRux Conditioning in Haploidentical HCT NCT06477549 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Recruiting | MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Tr NCT05564390 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | PTCy and ATG for MSD and MUD Transplants NCT06299462 | Instituto Nacional de Cancer, Brazil | Phase 1 / Phase 2 |
| Recruiting | Ziftomenib Maintenance Post Allo-HCT NCT06440135 | Massachusetts General Hospital | Phase 1 |
| Recruiting | A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia NCT06389292 | Ascentage Pharma Group Inc. | Phase 3 |
| Withdrawn | ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML NCT05622591 | Elucida Oncology | Phase 1 |
| Not Yet Recruiting | Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia NCT05319249 | German Cancer Research Center | Phase 1 / Phase 2 |
| Recruiting | Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoc NCT06419634 | Bristol-Myers Squibb | Phase 1 |
| Recruiting | Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leu NCT06195891 | City of Hope Medical Center | Phase 1 |
| Recruiting | A Study of GLB-001 in Patients With Myeloid Malignancies NCT06378437 | Hangzhou GluBio Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | MRD Response-adapted Allo-HSCT for Adverse-risk AML NCT06301425 | Peking University People's Hospital | N/A |
| Recruiting | Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACI NCT06055621 | Institut Paoli-Calmettes | Phase 2 |
| Recruiting | A Telehealth Advance Care Planning Intervention NCT05875805 | University of Rochester | N/A |
| Recruiting | Phase I Study of HC-7366 for Acute Myeloid Leukemia NCT06285890 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA) NCT06297551 | Suhu Liu | — |
| Recruiting | Vitamin A and D Supplementation in Allogeneic HCT NCT06508099 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Recruiting | Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant NCT06158828 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Recruiting | Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML NCT05986240 | Montefiore Medical Center | Phase 1 |
| Recruiting | Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignan NCT05800210 | University of Florida | Phase 2 |
| Recruiting | Refining the Role of Mid-induction Bone Marrow Biopsy in Acute Myeloid Leukemia: A Pilot Study NCT06323590 | University of Alabama at Birmingham | — |
| Recruiting | Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial NCT06355583 | Imperial College London | Phase 2 |
| Recruiting | Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents NCT05442216 | Joshua Zeidner | Phase 2 |
| Recruiting | Study of REM-422 in Patients With AML or Higher Risk MDS NCT06297941 | Remix Therapeutics | Phase 1 |
| Recruiting | A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia NCT06387069 | Hutchmed | Phase 3 |
| Active Not Recruiting | A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients NCT06928376 | Chinese PLA General Hospital | Phase 2 |
| Recruiting | A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia NCT05748197 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated A NCT05904106 | Technische Universität Dresden | Phase 2 |
| Not Yet Recruiting | Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS NCT06050941 | First Affiliated Hospital of Zhejiang University | Phase 2 |
| Completed | Music Therapy in Acute Leukemia Patients With Fatigue NCT06286332 | Chang Gung University | N/A |
| Not Yet Recruiting | BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children NCT06347458 | Guangzhou Bio-gene Technology Co., Ltd | Phase 1 |
| Recruiting | VA vs DA for Newly Diagnosed Hig-risk AML NCT05939180 | The First Affiliated Hospital of Soochow University | Phase 2 / Phase 3 |
| Withdrawn | DEC-C and Thioguanine for R/R AML NCT06351306 | Columbia University | Phase 2 |
| Withdrawn | Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS NCT05829434 | Uwe Platzbecker | Phase 2 |
| Recruiting | Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia NCT06197672 | Huda Salman | Phase 1 |
| Recruiting | A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, a NCT06191978 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies NCT06206174 | Shenzhen TargetRx Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected A NCT06058741 | AbbVie | — |
| Not Yet Recruiting | Personalized Medication Software for BCL-2 Inhibitor in AML Patients Using Machine Learning and Genomics NCT06295029 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | — |
| Completed | Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven NCT06030089 | Centre Hospitalier Universitaire de Nice | N/A |
| Recruiting | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT06001788 | Kura Oncology, Inc. | Phase 1 |
| Recruiting | CIML NK Cells With Venetoclax for AML NCT06152809 | Dana-Farber Cancer Institute | Phase 1 |
| Withdrawn | A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia NCT06113289 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Cladribine Venetoclax in Monocytic AML NCT06232655 | University of Colorado, Denver | Phase 2 |
| Recruiting | VAC Regimen for AML Patients Who Failed to Response to VA Regimen NCT06220162 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Unknown | Study of IBR733 Cell Injection in Acute Myeloid Leukemia NCT06234904 | Imbioray (Hangzhou) Biomedicine Co., Ltd. | Phase 1 |
| Recruiting | Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation NCT06138587 | Dana-Farber Cancer Institute | Phase 1 |
| Recruiting | Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvem NCT06111612 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Recruiting | Dynamics of Resistance Emergence to Azacitidine-based Therapies in Acute Myeloid Leukemia NCT06225128 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Hi NCT06146257 | GluBio Therapeutics Inc. | Phase 1 |
| Recruiting | Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML NCT06191263 | Ryvu Therapeutics SA | Phase 2 |
| Recruiting | Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents W NCT06221683 | Children's Hospital of Soochow University | Phase 2 |
| Recruiting | Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML NCT06232694 | The First Affiliated Hospital with Nanjing Medical University | N/A |
| Recruiting | Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML NCT06429098 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Active Not Recruiting | Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML NCT07437170 | The Children's Hospital of Zhejiang University School of Medicine | Phase 2 |
| Active Not Recruiting | Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagno NCT06034470 | Fred Hutchinson Cancer Center | Phase 1 |
| Active Not Recruiting | HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantati NCT06001385 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Recruiting | CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia NCT05672147 | City of Hope Medical Center | Phase 1 |
| Recruiting | A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid Leukemia NCT05189639 | Pfizer | — |
| Recruiting | Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Inel NCT06537843 | Hospital Municipal São José | Phase 2 |
| Active Not Recruiting | Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Child NCT06475820 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 2 / Phase 3 |
| Recruiting | A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Or NCT05587049 | AbbVie | — |
| Not Yet Recruiting | Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML NCT06133556 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Active Not Recruiting | Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients Wit NCT05716009 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Recruiting | A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Pat NCT06073769 | Bristol-Myers Squibb | — |
| Terminated | Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants Wit NCT06068868 | AbbVie | Phase 1 |
| Withdrawn | High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD NCT05895201 | Indiana University | Phase 1 / Phase 2 |
| Withdrawn | Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients NCT06180863 | Yale University | Phase 2 |
| Unknown | Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venet NCT06073730 | The Second Affiliated Hospital of Kunming Medical University | Phase 3 |
| Recruiting | Universal 4SCAR7U Targeting CD7-positive Malignancies NCT05995028 | Shenzhen Geno-Immune Medical Institute | Phase 1 |
| Recruiting | Universal CAR-T Cells Targeting AML NCT05995041 | Shenzhen Geno-Immune Medical Institute | Phase 1 |
| Recruiting | A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML) NCT05834244 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS NCT06046313 | First Affiliated Hospital of Zhejiang University | Phase 2 |
| Recruiting | Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Mali NCT05991908 | Shanghai Jiao Tong University School of Medicine | Phase 3 |
| Terminated | Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML NCT06110208 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | EARLY_Phase 1 |
| Active Not Recruiting | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T- NCT05377827 | Washington University School of Medicine | Phase 1 |
| Terminated | A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokine NCT06021600 | M.D. Anderson Cancer Center | Phase 1 |
| Withdrawn | A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as NCT05201183 | Naoyuki G. Saito, M.D., Ph.D. | Phase 1 / Phase 2 |
| Recruiting | Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemothera NCT06066242 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Active Not Recruiting | Muscle Dysfunction in Patients With Haematological Diseases NCT05150561 | Rigshospitalet, Denmark | — |
| Active Not Recruiting | Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant NCT04167683 | Rigshospitalet, Denmark | — |
| Active Not Recruiting | Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) NCT05744739 | Northwestern University | Phase 1 |
| Terminated | Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome NCT05961839 | Schrödinger, Inc. | Phase 1 |
| Recruiting | Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies NCT06034275 | Vincerx Pharma, Inc. | Phase 1 |
| Active Not Recruiting | NAC for Promoting Hematopoietic Recovery in Patients With Acute Myeloid Leukemia After Chemotherapy NCT06024031 | Peking University People's Hospital | Phase 2 |
| Unknown | Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy NCT06008405 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Enrolling By Invitation | PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9 NCT05212103 | Turku University Hospital | — |
| Recruiting | Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmac NCT06006403 | Chongqing Precision Biotech Co., Ltd | Phase 1 / Phase 2 |
| Unknown | A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection NCT05801835 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | N/A |
| Recruiting | A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia NCT06017258 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Active Not Recruiting | Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the NCT04994808 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Investigating Integrative Therapies for Symptom Management in Adults With Acute Leukemia NCT04185428 | University of Florida | N/A |
| Completed | Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia NCT05941585 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Enrolling By Invitation | Multi-omics Approach of Risk Stratification for Patients With de Novo Acute Myeloid Leukemia NCT05983172 | National Taiwan University Hospital | — |
| Active Not Recruiting | A Phase 1 Study of BMF-500 in Adults With Acute Leukemia NCT05918692 | Biomea Fusion Inc. | Phase 1 |
| Suspended | A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid L NCT05955261 | St. Jude Children's Research Hospital | Phase 2 |
| Recruiting | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, V NCT05735184 | Kura Oncology, Inc. | Phase 1 |
| Recruiting | A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer NCT05659732 | PharmaEngine | Phase 1 |
| Withdrawn | Clinical Study on Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in the Treatment of Acute Myeloid Leukem NCT05943314 | Guangzhou Bio-gene Technology Co., Ltd | N/A |
| Recruiting | The Maintenance Treatment of "ITIVA" in AML Patients NCT06256627 | Henan Cancer Hospital | N/A |
| Unknown | A Study of TQB3454 Tablets in Patients With Blood Tumors NCT06218771 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 / Phase 2 |
| Completed | A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) NCT05470140 | Wugen, Inc. | Phase 1 |
| Active Not Recruiting | Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy NCT05583552 | GCP-Service International West GmbH | Phase 2 |
| Withdrawn | A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participan NCT06362031 | AbbVie | — |
| Recruiting | Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular NCT05772559 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment NCT05580861 | Assistance Publique - Hôpitaux de Paris | Phase 1 / Phase 2 |
| Recruiting | MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies NCT05735717 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia ( NCT05580601 | Children's Hospital Medical Center, Cincinnati | Phase 1 / Phase 2 |
| Recruiting | RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT NCT05858814 | Guangdong Ruishun Biotech Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Geno NCT05260528 | Centre Hospitalier Universitaire de Nice | Phase 2 |
| Completed | Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/Refractory NCT06429670 | Hospices Civils de Lyon | — |
| Recruiting | A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes NCT05732103 | Chordia Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabi NCT05796570 | Franziska Wachter | Phase 2 |
| Recruiting | Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete NCT05909293 | The First Affiliated Hospital with Nanjing Medical University | N/A |
| Unknown | A Study on the Efficacy and Safety of Venetoclax Combined With HAA Regimen in Newly Diagnosed Young AML. NCT05893472 | ZePing Zhou | Phase 1 / Phase 2 |
| Unknown | Safety and Efficacy of Venetoclax in Combination With Azacitidine and HA Regimen in the Treatment of AML in th NCT05949762 | ZePing Zhou | Phase 1 / Phase 2 |
| Terminated | First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT05817058 | Affimed GmbH | Phase 1 |
| Active Not Recruiting | Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, a NCT05457556 | Children's Oncology Group | Phase 3 |
| Recruiting | PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT NCT05772273 | The First Affiliated Hospital of Soochow University | N/A |
| Withdrawn | Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients NCT03932318 | Actinium Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia NCT05458258 | University of Chicago | — |
| Withdrawn | GM-CLAG in Relapsed/Refractory FLT3-mutated AML NCT05330377 | Ayman H Qasrawi | Phase 1 |
| Completed | Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia NCT06068621 | Chinese PLA General Hospital | Phase 2 |
| Unknown | Safety and Efficacy of Allogenic NK Cells in Combination With Chemotherapy in the Treatment of r/r AML After A NCT05744440 | Xuzhou Medical University | EARLY_Phase 1 |
| Recruiting | Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML NCT05805098 | The First Affiliated Hospital of Soochow University | Phase 2 / Phase 3 |
| Terminated | A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-a NCT05447663 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Recruiting | Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Effica NCT05101551 | Norman J. Lacayo | Phase 1 |
| Recruiting | CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML NCT05558124 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Active Not Recruiting | A High Intensity Electronic Health Intervention for the Reduction of Learning Disparities in Childhood Cancer NCT05428176 | City of Hope Medical Center | N/A |
| Unknown | A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MD NCT05641259 | Guangzhou Lupeng Pharmaceutical Company LTD. | Phase 1 |
| Recruiting | BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome NCT05703542 | Eric Stephen Winer, MD | Phase 1 |
| Unknown | Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia NCT05918198 | Peking University People's Hospital | Phase 2 |
| Recruiting | Pilot Imaging Study of Leukemia NCT03633955 | University of Oklahoma | Phase 1 |